http://pmjournal.ir Reviwe Article

Summer 2023, Volume 8, Issue 30 (9-16)

Personalized Medicine for HIV Control: A Systematic Review Study

Shekoofeh Farahmandpour[1], Nastaran Dehghani[1], Asra Khalkhalizadeh[1], Paniz Hajihossein[1], Armin Nikdehqan[1*]

[1] Department of Biology, Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran.

**Corresponding author: Armin Nikdehqan, Department of Biology, Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran. Email: a.nikdehqan@yahoo.com.*

DOI: 10.22034/pmj.2023.2011747.1015

Submitted: 2023-04-27
Accepted: 2023-08-18

Keywords:
HIV infections
Personalized Medicine
Antiviral inhibitors
Gene-editing approach

Abstract:
There were more than thirty-eight million HIV infections worldwide. Combination antiretroviral therapy (cART) has progressed to the point where invisible viral loads are now feasible, and HIV carriers frequently lead almost everyday lives with considerably greater average life expectancies than in the past. However, there is still no cure for the disease. Even though the ailment usually advances to a chronic state, an individual's unique course of progression may differ significantly from the average and manifest distinctively for each patient. This diversity begs whether a typical treatment strategy is appropriate for a patient.

INTRODUCTION

AIDS is an illness that presents its victims with various issues (1). Human Immunodeficiency Virus (HIV) is the disease's primary causal agent (2). HIV severely harms the immune system. After this virus was discovered in the United States, the illness has transformed throughout the last several decades and is now spreading over the whole globe (3). A kind of T-lymphocyte cell called CD4 is damaged and destroyed by HIV because CD4 cell density in a healthy person's body ranges from 500 to 1500 cells per cubic meter but fewer than 200 in a person with the illness (4, 69). This harm accumulates over time and results in various illnesses in the patient, including cancer (5).

It is possible to mention bodily fluids, including blood, semen, vaginal secretions, and breast milk, as possible transmission routes for this illness(6). Lymph nodes that are enlarged, exhaustion, frequent fevers, headaches and other bodily pains, vomiting and nausea, weight gain, diarrhoea, vaginal and oral infections, pneumonia, and shingles are all signs of the chronic stage of HIV(7). Given that HIV affects a person's DNA, this illness is incurable, and there is no cure for its causes (8). However, efforts have been made to control this illness, and the only effective treatment is the use of antiviral medications that a doctor prescribes (9). If the illness is not controlled, the patient will contract AIDS, and their body will not be able to fight infectious diseases (10). Consequently, it makes a person more susceptible to illnesses like meningitis, oral thrush, and cytomegalovirus (11).

Because there is no treatment for this illness, it is best to follow the adage "prevention is better than cure" and practice good hygiene to avoid contracting HIV(12). For everyone to be aware of this illness and to pay greater attention to their health, the best course of action is to educate the public, particularly teens, about HIV and how this disease is spread. A person-centred medical approach may find the finest answers in this area (13).

Most HIV transmission routes have much to do with lifestyle, personal habits, and behaviors. For instance, using drugs, smoking, or engaging in unhealthful sexual behavior raise the risk of contracting the illness (14). Even though these habits are daily in specific groups and nations, they may be changed with the proper guidance and instruction (15). So, utilizing prescription medication may help to avoid this sickness. Uganda and Thailand are two nations that have succeeded in lowering the pace of the spread of this illness following the principles of personal medicine (16).

Lack of preventive and poor personal hygiene will lead to disorder in society and personal life. Individual health first ensures one's health, then the health of other family members, and lastly, in the second stage, the health of whole communities (17). It should not be overlooked that maintaining personal hygiene and health, including vaccination, altering habits and behaviours, and being aware of the hazards of HIV, may be managed with a personal medical approach (18).

HIV in children

A) nce of HIV in children

Children, who made up about 10% of new HIV infections worldwide and comprised an estimated 3.4 million HIV-positive children under 15 in 2010 (19), have been severely impacted by the HIV pandemic. Since introducing antiretroviral treatment (ART), child survival has considerably risen in resource-rich and resource-limited settings (20). Despite an increase in ART coverage, only around 34% of children under 15 who need treatment in low- and middle-income countries get it, compared to 68% of adults (21).

B) Risk of mother-to-child transmission

Researchers found 288 out of 11,285 kids (2.6%) had HIV-related diagnoses. The majority of children (272, 94.4%) were identified as having HIV by a positive HIV fast antibody test performed after the age of 12 months or by a positive HIV-1 DNA test (22). Only 16 out of 288, or 5.6%, of the youngsters had an HIV diagnosis that was considered severe. Infected with HIV at eight weeks: 0.7% (95% CI: 0.6-0.9) of the enrolling children (23). By the time they were 12 months old, 2.2% (95% CI: 1.9-2.5) of the children had been diagnosed; by the time they were 30 months old, 2.6% (95% CI: 2.3-2.9) (22). The cumulative incidence was 0.8% (95% CI: 0.7-1.0) by age eight weeks, 2.7% (95% CI: 2.4-3.1) by age 12 months, and 5.3% (95% CI: 4.7-5.9) by age 30 months in the weighted analysis, which takes into account unobserved test findings from children lost to follow-up or not tested (22).

C) Growth and development

Even without overt AIDS or wasting, children with PHIV tend to be shorter in height, have lower body weights, and enter puberty later than children without the virus (24). Numerous conditions, including viremia, symptomatic HIV infection, malabsorption, inflammation, mitochondrial toxicity, psychosocial conditions, nutritional deficiencies, aberrant nitrogen balance, and altered growth hormone production or action, are linked to this atypical growth (25). The date of pubertal start (Tanner stage2) was considerably delayed for 2086 PHIV compared to 453 HIV-exposed uninfected children according to research employing two large US longitudinal cohorts between 2000 and 2012. The research also discovered that among PHIV, longer HAART duration was linked with somewhat more normal pubertal onset and that higher VL and lower CD4% were related to more delayed pubertal onset (26). These findings imply that early access to HAART promotes more typical development patterns for PHIV (9). However, there are few findings from the SSA where children are more likely to experience malnutrition and other disorders linked to poor growth (27).

D)Sexual and reproductive health

It has been shown in studies that having an STI increases the risk of HIV acquisition and transmission (28), but it is less clear if those with HIV who are on HAART and have a well-controlled HIV infection are more at risk for STIs (29). There is less research on PHIV, despite several studies showing the significant incidence of STIs among adolescents and young adults who are HIV-positive by behavior (30). In comparison to matched, uninfected controls, a study of 638 PHIV-positive teenage girls in the PACTG 219C cohort found higher rates of condylomas acuminate, trichomoniasis, and cervical abnormalities, such as atypical cells, low-grade, squamous intraepithelial lesions, and



Fig 1. At least one child globally was infected with HIV every two minutes in 2020. (69)

high-grade squamous intraepithelial lesions (26). Compared to the general population, both groups of PHIV and behaviorally infected women in the United States had higher rates of pregnancy and premature births. PHIV women were significantly more likely to elect a pregnancy termination (26). In comparison to uninfected infants born to non-perinatally HIV-infected mothers, uninfected infants born to PHIV mothers were significantly shorter throughout the first year of life (after adjusting for confounding), according to a recent retrospective cohort study of 152 pregnancies in the United States (26). However, the significance of these findings is unclear. Only a small amount of data is available to guide sexual and reproductive therapies in PHIV (31). In a recent systematic analysis, it was determined that women's outcomes, such as the prevalence of HIV and STIs, the use of condoms and other contraceptives, and their retention in care, were better when sexual and reproductive health services were linked with HIV/AIDS services (32). As more people with HIV approach adolescence and adulthood, it is essential to look at more efficient service delivery systems for sexual and reproductive health care (33). Additionally, the seldom acknowledged problem of the sexual and reproductive health of PHIV-men must be addressed (26).

Antiviral inhibitors drug resistance in HIV

Human immunodeficiency virus type 1 (HIV-1) was first identified as the source of the HIV/AIDS epidemic in the early 1980s (34). Approximately 33 million people have perished from the illness in the last 40 years. The three viral enzymes, protease (PR), reverse transcriptase (RT), and integrase (IN), as well as various phases of the viral lifecycle, have all been the subject of multiple antiretroviral medication developments (35). The World Health Organization advises using these antiviral medications in combination with treatment because of their significant efficacy (35). Pre-exposure prophylaxis depends on using RT and IN inhibitors without an HIV vaccine. Treatment for HIV/AIDS relies heavily on antiviral medicines that specifically target the retroviral protease of the human immunodeficiency virus (HIV) (36). This therapy's main drawback is developing antiviral medication resistance, which affects many treated patients and builds up throughout treatment (37).

Types of drug resistance in HIV

A) Transmitted drug resistance

HIV drug-resistant strains may spread from patient to patient, causing newly infected individuals to carry drug-resistant viruses even if they have not yet started antiretroviral therapy. This is referred to as transferred medication resistance and poses a severe risk to the transmission of HIV (38, 62, 63).

B)Acquired drug resistance during antiretroviral treatment

Patients receiving antiretroviral therapy (ART) often see a gradual rise in acquired drug resistance over time (39).

C) Multi-class drug resistance

When a virus develops resistance to one medicine and then develops resistance to another drug from a different class, this phenomenon is known as multi-class drug resistance. Although it is theoretically feasible for a virus to acquire many medication-resistance mutations concurrently, the facts indicate that this is uncommon (40).

D) Resistance to the newer drugs

NRTIs, NNRTIs, and PIs were the only three main medication classes initially available for the treatment of HIV (41). However, the significant cross-resistance across these classes made it unlikely for another NNRTI to be helpful if a patient did not react to one (38). Elvitegravir and raltegravir are examples of integrase strand transfer inhibitors (INSTIs), CCR5 antagonists like maraviroc, and fusion inhibitors like enfuvirtide that were released into the market in 2003(42). There might also be wide genetic variations in drug resistance for the new medication classes. For instance, raltegravir and elvitegravir may resist single mutations, whereas newer integrase inhibitors like DTG and MK-2048 may resist numerous mutations (38). To assess how susceptible HIV is to various antiretroviral medications, resistance tests have been created. There are now two different kinds of tests: genotypic tests, which look for resistance mutations, and phenotypic tests, which gauge a virus's sensitivity to different medications in tissue-culture systems (43, 72).

Phenotypic resistance tests examine viruses' susceptibility to various medications in vitro, and the findings may be very instructive in a research context. However, because of its intricacy, expense, and time commitment (requiring more than a week to complete), this sort of assay is not appropriate for routine clinical testing. Genotypic resistance testing is an alternate strategy that entails sequencing the relevant viral genome segments and analyzing the sequence in light of the virus›s resistance phenotype (44, 64-66).

Forecasting the establishment of medication resistance requires knowing how HIV replicates during treatment (45). HIV infection that persists after treatment indicates the chance that the virus may continue to spread actively and lead to new mutations and medication resistance. On the other hand, the likelihood of new drug-resistance mutations arising from long-lived, chronically infected reservoirs is significantly lowered if treatment suppression successfully stops the infection from spreading (46).

Human immunodeficiency virus (HIV) presents

Table 1. Multi-class drug for HIV treatment.

Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) [61]	Non-nucleoside reverse transcriptase inhibitors (NNRTIs) [62]	Protease inhibitor (PI) [63]	Integrase inhibitors [64]	Post-binding inhibitor or monoclonal antibody [65]	Drugs based on integrase strand transfer inhibitor (INSTI) [66]	Drugs based on nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) [67]
Abacavir	Cabotegravir	Atazanavir	Cobategravir and Rilpivirine	Atazanavir + Cobicistat	Bictegravir + Tenofovir Alafenamide + Emtricitabine	Abacavir + Lamivudine
didanosine	Delavirdine	Darunavir	Cabotegravir	Darunavir + Cobicistat	Dolutegravir + Aabacavir + lamivudine	Abacavir + Lamivudine + Zidovudine
Emtricitabine	Doravirine	Fosamprenavir	Dolutegravir	Elvitegravir + TDF + FTC + Cobicistat	Dolutegravir + Rilpivirine	Tenofovir Alafenamide + Emtricitabine
lamivudine	Efavirenz	Indinavir	Elvitegravir	Elvitegravir + TAF + FTC + Cobicistat	Dolutegravir + lamivudine	Tenofovir disoproxil Fumarate + Emtricitabine
Stavudine	Etravirine	lopinavir + ritonavir	Raltegravir	---	Elvitgravir + Cobicistat + Tenofovir Alafenamide + Emtricitabine	Tenofovir disoproxil Ffumarate + lamivudine
Tenofovir alafenamide	Nevirapine	Nelfinavir	---	---	Elvetgravir + Cobicistat + Tenofovir Disoproxil Fumarate + Emtricitabine	Zidovudine + Lamivudine
Tenofovir disoproxil fumarate	Rilpivirin	Ritonavir	---	---	---	---
Zidovudine	---	Saquniavir	---	---	---	---
	---	Tipanavir	---	---	---	---

one of the highest evolutionary rates ever detected, and a combination of antiretroviral therapy is needed to overcome the plasticity of the virus population and control viral replication (47, 71). Conventional treatments cannot clear the latent reservoir, which remains the major obstacle towards a cure. Novel strategies, such as CRISPR/Cas9 gRNA-based genome editing, can permanently disrupt the HIV genome. However, HIV genome editing may accelerate viral escape, questioning the approach's feasibility (48). Here, we demonstrate that CRISPR/Cas9 targeting single HIV loci only partially inhibits HIV replication and facilitates rapid viral escape at the target site (49). A combinatorial approach of two strong gRNAs targeting different regions of the HIV genome can completely abrogate viral replication and prevent viral escape (50). Our data shows that the accelerating effect of gene editing on viral escape can be overcome. As such, gene editing may provide a future alternative to control HIV infection (51).

Efficient targeting and editing of HIV by CRISPR/Cas9 The researchers evaluated the ability of stably expressed gRNAs to target and edit HIV DNA. Two gRNA sequences designed to target the HIV-1 LTR region were expressed in a lentiviral vector with Cas9 endonuclease (52). GRNAs were intended to target the viral structural matrix protein, protease, reverse transcriptase, and integrase, all essential for virus replication (53). The researchers infected Jurkat cells containing a nearly complete copy of HIV with gRNA-containing lentiviruses that target the LTR region, the matrix structural protein, or the integrase enzyme (54). Deep sequence analysis revealed specific genome editing events at the target site in 100%, 76%, and 90.1% of the sequences for LTR6, MA3, and IN5 gRNAs, respectively (47). Therefore, the researchers focused on the LTR region and selected two gRNAs, LTR4 and LTR6, which target the SPI binding region and the TAR loop (47, 70).

Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection

Functional or sterilizing treatment can be achieved using gene editing technologies, which show promise both in vitro and in vivo. To be a successful treatment, gene editing efficiency needs to be increased. Successful gene editing technologies are a desirable alternative for HIV-1 therapy of the future due to their potential

advantages (55). All gene editing approaches must overcome obstacles before they can be developed into an appealing curative HIV-1 therapy. Any gene editing technique to combat HIV-1 will also face difficulties detecting and altering cells at various anatomical areas or altering precursor cells that eventually go to tissue sites. For any in vivo gene editing approach, a delivery system that can be transported to multiple locations will be highly beneficial (56). It is unclear if tissue-resident cells have been effectively changed using gene editing of HIV co-receptors in vivo. Nevertheless, the ability to engraft into various tissue compartments has been demonstrated when hematopoietic stem/progenitor cells are edited with a ZFN targeting CCR5(57). Infected NHPs' guts may be replenished with virus-repleted CD4 central memory T cells using these modified cells. The peripheral blood reservoir and all latent viral reservoirs are anticipated unaffected by co-receptor editing for HIV-1 infection. For instance, it would be less likely to target tissue-resident cells successfully (58). Absent a greater knowledge of the mechanism underlying the "Cure" of the "Berlin Patient," ablation of the CCR5 receptor in CD4 T cells has come to dominate research in this field (59). Delivering Cas9/sgRNA ribonucleoproteins directly to infected cells rather than plasmids has reduced off-target effects. In a recent study, R691A SpCas9 mutant delivery using human HSPCs revealed negligible off-target editing while maintaining excellent on-target activity (60). Human CD4 T cells in vitro CXCR4 expression was interfered with using Cas9 RNPs (61, 67, 68).

CONCLUSION

According to the current research, despite being at the center of the arena—providing the stage of concern its raison —people being treated for HIV were both involved by others and marginalized. Members of professional organizations whose specialized professional interests are prioritized in the field should not overlook patients' concerns. In addition to the particular aims of the communities engaged thus far, the overarching goal of guaranteeing patients' survival must be made more tangible and enriched by patients' perspectives: What do HIV-positive patients require today? How might currently existing support networks, such as DAH, help articulate and formulate such requirements during higher-level decision-making processes on appropriate therapies and developing new tools? Single-pill regimens can assure the continued existence of most HIV-positive persons without problems. Is it the proper path to create new and more precise HIV TOS, such as NGS-based HIV TOS, which might improve digitalization and deeper analysis of patient data? Or may other activities that prioritize patients' health(care) requirements be more beneficial to the health and well-being of HIV-positive people? We encourage participatory programs that incorporate all stakeholders and a diverse range of HIV-positive persons to address the question of which HIV TOS improvements should be prioritized.

Acknowledgements

The authors would like to thank the Biotechnology Research Centre staff members of the Parsian BioProducts Company (PBP) in Iran. This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data generated or analyzed during this study are included in this article.

REFERENCES

1.Fauk NK, Gesesew HA, Mwanri L, Hawke K, Ward PR. HIV-related challenges and women's self-response: A qualitative study with women living with HIV in Indonesia. Plos one. 2022 Oct 10;17(10):e0275390.

2. Uwishema O, Ayoub G, Badri R, Onyeaka H, Berjaoui C, Karabulut E, Anis H, Sammour C, Mohammed Yagoub FE, Chalhoub E. Neurological disorders in HIV: hope despite challenges. Immunity, inflammation and disease. 2022 Mar;10(3):e591.

3.Rao AK, Schrodt CA, Minhaj FS, Waltenburg MA, Cash-Goldwasser S, Yu Y, Petersen BW, Hutson C, Damon IK. Interim clinical treatment considerations for severe manifestations of mpox—United States, February 2023. Morbidity and Mortality Weekly Report. 2023 Mar 3;72(9):232.

4.Mangal S, Misra OP, Dhar J. Fractional-order deterministic epidemic model for the spread and control of HIV/AIDS with special reference to Mexico and India. Mathematics and Computers in Simulation. 2023 Aug 1;210:82-102.

5.Hoeijmakers JH. DNA damage, aging, and cancer. New England Journal of Medicine. 2009 Oct 8;361(15):1475-85.

6.Centers for Disease Control (US). Recommendations for prevention of HIV transmission in health-care settings. US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1987.

7.Asadipour E, Asgari M, Mousavi P, Piri-Gharaghie T, Ghajari G, Mirzaie A. Nano-Biotechnology and Challenges of Drug Delivery System in Cancer Treatment Pathway. Chemistry & Biodiversity. 2023 Mar 1:e202201072.

8.Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral research. 2010 Jan 1;85(1):1-8.

9.Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.

Health psychology. 2000 Mar;19(2):124.
10.Piri Gharaghie T, Beiranvand S, Hajimohammadi S. Comparison of Antifungal Effects of Aquatic and Alcoholic Extract of Mentha pulegium L. With Fluconazole on Growth of Candida Albicans. Developmental Biology. 2021 May 22;13(2):7-18.
11.Xiao J, Gao G, Li Y, Zhang W, Tian Y, Huang Y, Su W, Han N, Yang D, Zhao H. Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary care hospital, China. PloS one. 2013 Oct 25;8(10):e75915.
12.Edison T. Future positive. The Great Health Dilemma: Is Prevention Better Than Cure?. 2021 May 27:179.
13.McAuliffe L, Bauer M, Nay R. Barriers to the expression of sexuality in the older person: the role of the health professional. International Journal of Older People Nursing. 2007 Mar;2(1):69-75.
14.Crossley ML. The perils of health promotion and the 'barebacking'backlash. Health:. 2002 Jan;6(1):47-68.
15.Settlage J, Southerland S. Teaching science to every child: Using culture as a starting point. Routledge; 2012 Apr 23.
16.Green EC. Rethinking AIDS prevention: Learning from successes in developing countries. Greenwood Publishing Group; 2003 Nov 30.
17.Jorm AF. Mental health literacy: empowering the community to take action for better mental health. American psychologist. 2012 Apr;67(3):231.
18.Piri Gharaghie T, Beiranvand S, Ghadiri A, Hajimohammadi S. A Review of Bioinformatics Studies on the Function of Structural and Nonstructural Proteins and the Level of Glycoprotein Inhibiting Heme Metabolism by SARS-CoV-2 Virus. Jundishapur Scientific Medical Journal. 2022 May 22;21(2):176-93.
19.Lindegren ML, Kennedy CE, Bain-Brickley D, Azman H, Creanga AA, Butler LM, Spaulding AB, Horvath T, Kennedy GE, Cochrane HIV/AIDS Group. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database of Systematic Reviews. 1996 Sep 1;2012(10).
20.Musoke PM, Fergusson P. Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings. The American journal of clinical nutrition. 2011 Dec 1;94(6):1716S-20S.
21.Piri-Gharaghie T, Zarinnezhad A, Naghian B, Babaei R. Molecular detection of fungal APR1 gene in serum of multiple sclerosis patients: a personalized medicine research. Personalized Medicine Journal. 2022 Jun 1;7(25):15-24.
22.Haas AD, van Oosterhout JJ, Tenthani L, Jahn A, Zwahlen M, Msukwa MT, Davies MA, Tal K, Phiri N, Spoerri A, Chimbwandira F. HIV transmission and retention in care among HIV-exposed children enrolled in Malawi's prevention of mother-to-child transmission programme. Journal of the International AIDS Society. 2017;20(1):21947
23.Pegues DA, Engelgau MM, Woernle CH. Prevalence of illicit drugs detected in the urine of women of childbearing age in Alabama public health clinics. Public Health Reports. 1994 Jul;109(4):530.
24.Taghiloo S, Ghajari G, Zand Z, Kabiri-Samani S, Kabiri H, Rajaei N, Piri-Gharaghie T. Designing Alginate/Chitosan Nanoparticles Containing Echinacea angustifolia: A Novel Candidate for Combating Multidrug-Resistant Staphylococcus aureus. Chemistry & Biodiversity. 2023 Jul;20(7):e202201008.
25.Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics. 2019 Aug 7;9(3):91.
26.Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM. The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. Journal of the International AIDS Society. 2015 Dec;18:20258.
27.Christian AK, Dake FA. Profiling household double and triple burden of malnutrition in sub-Saharan Africa: prevalence and influencing household factors. Public Health Nutrition. 2022 Jun;25(6):1563-76.
28.Ward H, Rönn M. The contribution of STIs to the sexual transmission of HIV. Current Opinion in HIV and AIDS. 2010 Jul;5(4):305.
29.Williamson LM, Dodds JP, Mercey DE, Hart GJ, Johnson AM. Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK. Aids. 2008 May 31;22(9):106.
30.Mellins CA, Tassiopoulos K, Malee K, Moscicki AB, Patton D, Smith R, Usitalo A, Allison SM, Van Dyke R, Seage III, for the Pediatric HIV-AIDS Cohort Study GR. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS patient care and STDs. 2011 Jul 1;25(7):413-22.
31.Duflo E, Dupas P, Kremer M. Education, HIV, and early fertility: Experimental evidence from Kenya. American Economic Review. 2015 Sep 1;105(9):2757-97.
32.Slabbert M, Venter F, Gay C, Roelofsen C, Lalla-Edward S, Rees H. Sexual and reproductive health outcomes among female sex workers in Johannesburg and Pretoria, South Africa: Recommendations for public health programmes. BMC Public Health. 2017 Jul;17:17-27.
33.Hughes J, McCauley AP. Improving the fit: adolescents' needs and future programs for sexual and reproductive health in developing countries. Studies in family planning. 1998 Jun 1:233-45.
34.Becken B, Multani A, Padival S, Cunningham CK. Human immunodeficiency virus I: history, epidemiology, transmission, and pathogenesis. Introduction to Clinical Infectious Diseases: A Problem-Based Approach. 2019:417-23.
35.Weber IT, Wang YF, Harrison RW. HIV protease: Historical perspective and current research. Viruses. 2021 May 6;13(5):839.
36.Andrews KT, Fairlie DP, Madala PK, Ray J, Wyatt DM, Hilton PM, Melville LA, Beattie L, Gardiner DL, Reid RC, Stoermer MJ. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrobial agents and

chemotherapy. 2006 Feb;50(2):639-48.
37.Gianella S, Richman DD. Minority variants of drug-resistant HIV. The Journal of infectious diseases. 2010 Sep 1;202(5):657-66.
38.Pennings PS. HIV drug resistance: problems and perspectives. Infectious disease reports. 2013 Jun 6;5(Suppl 1).
39.Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. The Journal of infectious diseases. 2003 Feb 15;187(4):683-6
40.Peng X, Xu Y, Huang Y, Zhu B. Intrapatient Development of Multi-Class Drug Resistance in an Individual Infected with HIV-1 CRF01_AE. Infection and Drug Resistance. 2021 Aug 25:3441-8.
41.Yeni P. Update on HAART in HIV. Journal of hepatology. 2006 Jan 1;44:S100-3.
42.Pau AK, George JM. Antiretroviral therapy: current drugs. Infectious Disease Clinics. 2014 Sep 1;28(3):371-402.
43.Clavel F, Hance AJ. HIV drug resistance. New England Journal of Medicine. 2004 Mar 4;350(10):1023-35.
44.Lengauer T, Pfeifer N, Kaiser R. Personalized HIV therapy to control drug resistance. Drug Discovery Today: Technologies. 2014 Mar 1;11:57-64.
45.Rong L, Feng Z, Perelson AS. Emergence of HIV-1 drug resistance during antiretroviral treatment. Bulletin of mathematical biology. 2007 Aug;69:2027-60.
46.Cortez KJ, Maldarelli F. Clinical management of HIV drug resistance. Viruses. 2011 Apr;3(4):347-78.
47.Lebbink RJ, de Jong DC, Wolters F, Kruse EM, van Ham PM, Wiertz EJ, Nijhuis M. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Scientific reports. 2017 Feb 8;7(1):41968.
48.Herskovitz J, Hasan M, Patel M, Kevadiya BD, Gendelman HE. Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy. HIV Reservoirs: Methods and Protocols. 2022:429-45.
49.Ophinni Y, Miki S, Hayashi Y, Kameoka M. Multiplexed tat-targeting CRISPR-Cas9 protects T cells from acute HIV-1 infection with inhibition of viral escape. Viruses. 2020 Oct 28;12(11):1223.
50.Wang G, Zhao N, Berkhout B, Das AT. A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures. Cell reports. 2016 Dec 13;17(11):2819-26.
51.Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature reviews Drug discovery. 2019 May;18(5):358-78.
52.Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas based antiviral strategies against HIV-1. Virus research. 2018 Jan 15;244:321-32.
53.Darlix JL, Godet J, Ivanyi-Nagy R, Fossé P, Mauffret O, Mély Y. Flexible nature and specific functions of the HIV-1 nucleocapsid protein. Journal of molecular biology. 2011 Jul 22;410(4):565-81.
54.Piri Gharaghie T, Doosti A, Mirzaei SA. Detection of T6SS secretory system and membrane purine involved in antibiotic resistance in multidrug-resistant Acinetobacter baumannii isolates. Journal of Microbial World. 2021 May 22;14(1):47-58.
55.Allen AG, Chung CH, Atkins A, Dampier W, Khalili K, Nonnemacher MR, Wigdahl B. Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection. Frontiers in microbiology. 2018 Dec 17;9:2940.
56.Conniot J, Talebian S, Simões S, Ferreira L, Conde J. Revisiting gene delivery to the brain: silencing and editing. Biomaterials Science. 2021;9(4):1065-87.
57.Allen AG. Utilizing the CRISPR/Cas9 System to Cure HIV-1 Infection. Drexel University; 2020.
58.Pankrac JP. Development and Evaluation of a Heterogenous Virus-Like Particle (VLP) Formulation to Achieve HIV-1 Latency Reversal and Cure (Doctoral dissertation, The University of Western Ontario (Canada)).
59.Yu S, Yao Y, Xiao H, Li J, Liu Q, Yang Y, Adah D, Lu J, Zhao S, Qin L, Chen X. Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to both X4-and R5-tropic human immunodeficiency virus type 1 infection. Human gene therapy. 2018 Jan 1;29(1):51-67.
60.Knipping F, Newby GA, Eide CR, McElroy AN, Nielsen SC, Smith K, Fang Y, Cornu TI, Costa C, Gutierrez-Guerrero A, Bingea SP. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing. Molecular Therapy. 2022 Jan 5;30(1):130-44.
61.Li S, Holguin L, Burnett JC. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Molecular Therapy-Methods & Clinical Development. 2022 Mar 10;24:321-31.
62.Holec AD, Mandal S, Prathipati PK, Destache CJ. Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. Current HIV research. 2017 Dec 1;15(6):411-21.
63.Vanangamudi M, Kurup S, Namasivayam V. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): A brief overview of clinically approved drugs and combination regimens. Current opinion in pharmacology. 2020 Oct 1;54:179-87.
64.Bergin H. Cardiovascular side effects of the antiretroviral agents rilpivirine, efavirenz, etravirine and abacavir: possible underlying mechanisms (Doctoral dissertation, University of Brighton).
65.Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020 Nov;80(16):1649-76.
66.Siller Jr A, Jebain J, Jinadatha C, Tyring SK. Mechanisms of Retroviral Resistance. InOvercoming Antimicrobial Resistance of the Skin 2021 May 8 (pp. 75-90). Cham: Springer International Publishing.
67.Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide:

a review in HIV-1 infection. Drugs. 2018 Nov;78:1817-28.
68.Waters L, Mehta V, Gogtay J, Boffito M. The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. Journal of Virus Eradication. 2021 Mar 1;7(1):100028.
69.Nike Adebowale-Tambe. HIV: Nonchalance, Ignorance, TBAs, others threaten Nigeria's efforts to end mother-to-child transmission. August 1, 2022.
70.Piri-Gharaghie T, Ghajari G, Hassanpoor M, Jegargoshe-Shirin N, Soosanirad M, Khayati S, Farhadi-Biregani A, Mirzaei A. Investigation of antibacterial and anticancer effects of novel niosomal formulated Persian Gulf Sea cucumber extracts. Heliyon. 2023 Mar 1;9(3).
71.Piri-Gharaghie T, Doosti A, Mirzaei SA. Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii. AMB Express. 2023 Dec;13(1):1-6.
72.Piri Gharaghie T, Hajimohammadi S. Comparison of anti-candida effects of aqueous, ethanolic extracts and essential oil of E. angustifolia with fluconazole on the growth of clinical strains of Candida. New Cellular and Molecular Biotechnology Journal. 2021 Jul 10;11(43):25-38.